[Effectiveness of topical bevacizumab in bilateral primary lipid keratopathy]

Arch Soc Esp Oftalmol. 2011 Nov;86(11):374-6. doi: 10.1016/j.oftal.2011.05.029. Epub 2011 Sep 9.
[Article in Spanish]

Abstract

Case report: A 75-year-old man with bilateral idiopathic lipid keratopathy underwent a penetrating keratoplasty in the left eye. One month later, there was deep corneal neovascularisation extending across the bed and the graft-host interface, with a whitish opacity surrounding the vessels. Topical bevacizumab (25mg/mL) was administered 4 times daily for 2 months with partial regression of corneal neovascularization.

Discussion: Topical bevacizumab may be useful in preventing a recurrence of lipid deposition after penetrating keratoplasty in patients with bilateral primary lipid keratopathy, although its long-term efficacy needs to be assessed.

Publication types

  • Case Reports

MeSH terms

  • Administration, Ophthalmic
  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bevacizumab
  • Corneal Neovascularization / diagnostic imaging
  • Corneal Neovascularization / drug therapy*
  • Corneal Neovascularization / etiology
  • Corneal Opacity / complications
  • Corneal Opacity / surgery*
  • Humans
  • Keratoplasty, Penetrating
  • Lipids
  • Male
  • Microscopy, Acoustic
  • Secondary Prevention

Substances

  • Antibodies, Monoclonal, Humanized
  • Lipids
  • Bevacizumab